Market News & Trends
Celldex Presents Positive Interim Results From Phase 1 Study
Celldex Therapeutics, Inc. recently presented interim data from the company’s CD40 agonist program in a late-breaking poster session today at the American Association for Cancer…
Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma
Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of advanced…
Calithera Biosciences Initiates Phase 1/2 Trial; Part of Pfizer Collaboration
Calithera Biosciences, Inc. recently announced the first patient has been treated in the Phase 1/2 open-label clinical trial of the glutaminase inhibitor telaglenastat (CB-839) in…
Race Oncology Files IND With FDA for Cancer Drug
Race Oncology Limited recently announced the US Food and Drug Administration has received its Investigational New Drug (IND) application for the company’s cancer drug Bisantrene.…
Skyrizi Approval in Japan Crucial for AbbVie as Biosimilar Competition Looms Large on Humira
At a time when pricing and reimbursement pressure is mounting on its blockbuster RA drug Humira (adalimumab) in the US and biosimilar competition looms large…
Novel Compound for Treating TBI Demonstrates Positive Results
Ischemix, Inc. recently announced significant results from a randomized, double-blinded, placebo-controlled preclinical study of its drug, CMX-2043, for the treatment of TBI. The company plans to…
Swedish Biomimetics 3000 Ltd Invents Groundbreaking Continuous Peptide Manufacturing Process
μLOT is an entirely new approach to manufacturing of therapeutic peptides, which promises to completely replace traditional large-scale batch manufacturing. The µLOT technology platform provides…
ExCellThera Announces Clearance by FDA & Health Canada for New Clinical Trials
ExCellThera Inc. recently announced its lead technology, ECT-001, will be used as part of two new clinical trials in patients with high-risk leukemia. The announcement…
Cytovation Initiates Clinical Development Program for First-in-Class Agent for Tumor Immunotherapy
Cytovation AS recently announced the first patients have been treated in a Phase I clinical study with CyPep-1, a novel therapeutic agent being developed as…
NapaJen Pharma & Astellas Pharma Establish Research Collaboration for Discovery & Development of Novel Oligonucleotides
NapaJen Pharma, Inc. recently announced it has entered into a research collaboration with Astellas Pharma Inc. for the discovery and development of novel oligonucleotide therapeutics.…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….